Minorities in clinical trials
This article was originally published in The Tan Sheet
Executive SummaryEvening meeting to examine role of FDA, institutional review boards, other stakeholders "in the protection of human subjects in clinical trials as it relates to minority participation" slated for Aug. 22. Meeting will take place from 7:30 p.m.-9:30 p.m. at Meharry Medical School in Nashville, Tenn. For more information, contact FDA's Sandra Baxter at 615-781-5385...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.